Management of the metabolic syndrome - nicotinic acid

被引:13
作者
Meyers, CD
Kashyap, ML
机构
[1] Vet Affairs Long Beach Healthcare Syst, Atherosclerosis Res Ctr, Long Beach, CA 90822 USA
[2] Vet Affairs Long Beach Healthcare Syst, Gerontol Sect, Long Beach, CA 90822 USA
[3] Univ Calif Irvine, Dept Med, Div Cardiol, Irvine, CA 92717 USA
关键词
D O I
10.1016/j.ecl.2004.03.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nicotinic acid effectively treats each of the common lipid abnormalities found in the metabolic syndrome, and much progress has recently been made in understanding its mechanisms of action. Early concern that nicotinic acid can precipitate or worsen diabetes has been eased with recent trials, which demonstrated its safety and effectiveness in insulin-resistant states. Furthermore, nicotinic acid prevents cardiovascular disease and death in persons with a high prevalence of risk factors for the metabolic syndrome. When used by an experienced physician and taken by a motivated patient, nicotinic acid can be safe and effective in treating the dyslipidemia of the metabolic syndrome.
引用
收藏
页码:557 / +
页数:20
相关论文
共 71 条
[1]   NICOTINIC-ACID INHIBITS ADIPOCYTE ADENYLATE-CYCLASE IN A HORMONE-LIKE MANNER [J].
AKTORIES, K ;
JAKOBS, KH ;
SCHULTZ, G .
FEBS LETTERS, 1980, 115 (01) :11-14
[2]   INFLUENCE OF NICOTINIC ACID ON SERUM CHOLESTEROL IN MAN [J].
ALTSCHUL, R ;
HOFFER, A ;
STEPHEN, JD .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1955, 54 (02) :558-559
[3]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[4]   Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia [J].
Aronov, DM ;
Keenan, JM ;
Akhmedzhanov, NM ;
Perova, NV ;
Oganov, RY ;
Kiseleva, NY .
ARCHIVES OF FAMILY MEDICINE, 1996, 5 (10) :567-575
[5]   HIGH-DENSITY LIPOPROTEIN METABOLISM IN MAN [J].
BLUM, CB ;
LEVY, RI ;
EISENBERG, S ;
HALL, M ;
GOEBEL, RH ;
BERMAN, M .
JOURNAL OF CLINICAL INVESTIGATION, 1977, 60 (04) :795-807
[6]   Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].
Brown, BG ;
Zhao, XQ ;
Chait, A ;
Fisher, LD ;
Cheung, MC ;
Morse, JS ;
Dowdy, AA ;
Marino, EK ;
Bolson, EL ;
Alaupovic, P ;
Frohlich, J ;
Albers, JJ ;
Serafini, L ;
Huss-Frechette, E ;
Wang, S ;
DeAngelis, D ;
Dodek, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592
[7]   REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298
[8]   ATTENUATION OF THE SYNTHESIS OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 BY NIACIN - A POTENTIAL LINK BETWEEN LIPID-LOWERING AND FIBRINOLYSIS [J].
BROWN, SL ;
SOBEL, BE ;
FUJII, S .
CIRCULATION, 1995, 92 (04) :767-772
[9]   Macular edema associated with nicotinic acid (niacin) [J].
Callanan, D ;
Blodi, BA ;
Martin, DF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (21) :1702-1702
[10]   15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN [J].
CANNER, PL ;
BERGE, KG ;
WENGER, NK ;
STAMLER, J ;
FRIEDMAN, L ;
PRINEAS, RJ ;
FRIEDEWALD, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) :1245-1255